Patents by Inventor Reinhold Penner

Reinhold Penner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9164102
    Abstract: The invention relates, in part, to methods useful in identifying molecules, that bind TRPM4b, which modulate TRPM4b ion channel activity, and/or which alter expression of TRPM4b within cells. The TRPM4b channels as described herein contain TRPM4b polypeptides, which are in turn encoded by TRPM4b nucleic acids. The ion channels described herein are preferably formed in HEK-293 cells from one or more novel TRPM4b polypeptides, which exhibit one or more of the unique TRPM4b properties described herein.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: October 20, 2015
    Assignee: The Queen's Medical Center
    Inventor: Reinhold Penner
  • Patent number: 8828674
    Abstract: The invention provides methods and compositions for determining the identity of CRACM homologs underlying Icrac activity in cells.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: September 9, 2014
    Assignee: The Queen's Medical Center
    Inventors: Reinhold Penner, Andrea Fleig
  • Patent number: 8669257
    Abstract: The present invention provides compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein each of W, Q, R1, R2, R3, R4, R5, m, and n is as defined herein, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: March 11, 2014
    Assignee: The Johns Hopkins University
    Inventors: Jun O. Liu, Yunzhao Ren, Fan Pan, Curtis R. Chong, Reinhold Penner, Jonathan R. Behr
  • Patent number: 8580525
    Abstract: The present invention relates to the identification and isolation of a novel family of ATP regulated calcium transmembrane channel polypeptides designated herein as “LTRPC7” (Long Transient Receptor Potential Channel). Channels comprising these polypeptides close in response to concentrations of cytoplasmic ATP in the millimolar range, are subject to inhibition by high intracellular levels of calcium and/or magnesium, and do not respond to depletion or reduction in intracellular calcium stores. The invention further relates to the methods of utilizing LTRPC7 for binding, and the methods for modulating LTRPC7 activity and for measuring LTRPC2 permeability. The invention further relates to the methods of modulating expression of LTRPC7.
    Type: Grant
    Filed: May 28, 2008
    Date of Patent: November 12, 2013
    Assignee: The Queen's Medical Center
    Inventors: Reinhold Penner, Andrea Fleig
  • Patent number: 8148083
    Abstract: The invention relates to methods useful in identifying candidate agents that modulate insulin secretion from an insulin secreting cell, where such molecules modulate TRPM4 activity and expression in the insulin secreting cell.
    Type: Grant
    Filed: May 25, 2007
    Date of Patent: April 3, 2012
    Assignee: The Queen's Medical Center
    Inventors: Reinhold Penner, Andrea Fleig
  • Publication number: 20110230368
    Abstract: The present invention provides high throughput assays for TRPM7 activity. The present invention encompasses methods and compositions for screening a sample for inhibitors of TRPM7, including methods and compositions for competitive high throughput assays.
    Type: Application
    Filed: October 29, 2010
    Publication date: September 22, 2011
    Applicant: The Queen's Medical Center
    Inventors: Reinhold PENNER, Andrea Fleig, F. David Horgen
  • Patent number: 7960129
    Abstract: The present invention provides assays and methods for determining levels of STIM2 activity, thus providing tools for the characterization and study of the regulation of intracellular calcium levels.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: June 14, 2011
    Assignee: The Queen's Medical Center
    Inventors: Reinhold Penner, Andrea Fleig
  • Publication number: 20100330156
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: March 22, 2010
    Publication date: December 30, 2010
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jun O. LIU, Yunzhao REN, Fan PAN, Curtis R. CHONG, Reinhold PENNER, Jonathan R. BEHR
  • Patent number: 7723075
    Abstract: The invention relates to methods useful in identifying molecules that bind TRPM5, which modulate TRPM5 ion channel activity, and/or which alter expression of TRPM5 within cells. The TRPM5 channels as described herein contain TRPM5 polypeptides, which are in turn encoded by TRPM5 nucleic acids. The ion channels described herein are preferably formed in HEK-293 cells from one or more novel TRPM5 polypeptides, which exhibit one or more of the unique TRPM5 properties described herein.
    Type: Grant
    Filed: February 23, 2004
    Date of Patent: May 25, 2010
    Assignee: The Queens's Medical Center
    Inventors: Reinhold Penner, Andrea Flieg
  • Publication number: 20090209435
    Abstract: The invention relates, in part, to methods useful in identifying molecules, that bind TRPM4b, which modulate TRPM4b ion channel activity, and/or which alter expression of TRPM4b within cells. The TRPM4b channels as described herein contain TRPM4b polypeptides, which are in turn encoded by TRPM4b nucleic acids. The ion channels described herein are preferably formed in HEK-293 cells from one or more novel TRPM4b polypeptides, which exhibit one or more of the unique TRPM4b properties described herein.
    Type: Application
    Filed: October 30, 2007
    Publication date: August 20, 2009
    Applicant: The Queen's Medical Center
    Inventor: Reinhold Penner
  • Publication number: 20090098546
    Abstract: The present invention relates to the identification and isolation of a novel family of ATP regulated calcium transmembrane channel polypeptides designated herein as “LTRPC7” (Long Transient Receptor Potential Channel). Channels comprising these polypeptides close in response to concentrations of cytoplasmic ATP in the millimolar range, are subject to inhibition by high intracellular levels of calcium and/or magnesium, and do not respond to depletion or reduction in intracellular calcium stores. The invention further relates to the methods of utilizing LTRPC7 for binding, and the methods for modulating LTRPC7 activity and for measuring LTRPC2 permeability. The invention further relates to the methods of modulating expression of LTRPC7.
    Type: Application
    Filed: May 28, 2008
    Publication date: April 16, 2009
    Applicant: The Queen's Medical Center
    Inventors: Reinhold Penner, Andrea Fleig
  • Publication number: 20090053753
    Abstract: The invention provides methods and compositions for determining the identity of CRACM homologs underlying Icrac activity in cells.
    Type: Application
    Filed: March 21, 2008
    Publication date: February 26, 2009
    Applicant: The Queen's Medical Center
    Inventors: Reinhold PENNER, Andrea Fleig
  • Publication number: 20090023177
    Abstract: The present invention provides assays and methods for determining levels of STIM2 activity, thus providing tools for the characterization and study of the regulation of intracellular calcium levels.
    Type: Application
    Filed: March 21, 2008
    Publication date: January 22, 2009
    Applicant: The Queen's Medical Center
    Inventors: Reinhold PENNER, Andrea Fleig
  • Patent number: 7452675
    Abstract: The invention relates, in part, to methods useful in identifying molecules, that bind TRPM4b, which modulate TRPM4b ion channel activity, and/or which alter expression of TRPM4b within cells. The TRPM4b channels as described herein contain TRPM4b polypeptides, which are in turn encoded by TRPM4b nucleic acids. The ion channels described herein are preferably formed in HEK-293 cells from one or more novel TRPM4b polypeptides, which exhibit one or more of the unique TRPM4b properties described herein.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: November 18, 2008
    Assignee: The Queen's Medical Center
    Inventors: Reinhold Penner, Andrea Fleig
  • Publication number: 20080096227
    Abstract: The invention relates to use of a calcium release activated Ca+2 (CRAC) channel (CRACM) such as CRACM1 and CRACM2 to identify bioactive agents which can modulate store operated calcium entry and CRAC channel activity. The invention further relates to the use of recombinant nucleic acids that encode CRACM. One aspect of the invention includes methods of determining binding of candidate bioactive agents to a CRACM polypeptide and for determining modulation of CRACM polypeptide activity as it affects CRAC channel permeability. The invention further relates to methods and compositions modulating the cellular expression of the nucleic acids that encode CRACM.
    Type: Application
    Filed: April 10, 2007
    Publication date: April 24, 2008
    Inventors: Reinhold Penner, Andrea Fleig, Jean-Pierre Kinet
  • Publication number: 20080039336
    Abstract: The invention relates to methods useful in identifying candidate agents that modulate insulin secretion from an insulin secreting cell, where such molecules modulate TRPM4 activity and expression in the insulin secreting cell.
    Type: Application
    Filed: May 25, 2007
    Publication date: February 14, 2008
    Applicant: The Queen's Medical Center
    Inventors: Reinhold Penner, Andrea Fleig
  • Publication number: 20050202472
    Abstract: The present invention relates to the identification and isolation of a novel family of ADP ribose (“ADPR) regulated calcium transmembrane channel polypeptides designated herein as “LTRPC2” (Long Transient Receptor Potential Channel). Channels comprising these polypeptides open in response to concentrations of cytoplasmic ADPR in the micromolar range, exhibit enhanced activity in the presence of high intracellular levels of calcium, and do not respond to depletion or reduction in intracellular calcium stores. The invention further relates to the methods of utilizing LTRPC2 for binding, and the methods for modulating LTRPC2 activity and for measuring LTRPC2 permeability. The invention further relates to the methods of modulating expression of LTRPC2.
    Type: Application
    Filed: January 12, 2005
    Publication date: September 15, 2005
    Inventors: Reinhold Penner, Andrea Fleig
  • Publication number: 20050019830
    Abstract: The invention relates to methods useful in identifying molecules that bind TRPM5, which modulate TRPM5 ion channel activity, and/or which alter expression of TRPM5 within cells. The TRPM5 channels as described herein contain TRPM5 polypeptides, which are in turn encoded by TRPM5 nucleic acids. The ion channels described herein are preferably formed in HEK-293 cells from one or more novel TRPM5 polypeptides, which exhibit one or more of the unique TRPM5 properties described herein.
    Type: Application
    Filed: February 23, 2004
    Publication date: January 27, 2005
    Inventors: Reinhold Penner, Andrea Flieg
  • Publication number: 20030143557
    Abstract: The invention relates, in part, to methods useful in identifying molecules, that bind TRPM4b, which modulate TRPM4b ion channel activity, and/or which alter expression of TRPM4b within cells. The TRPM4b channels as described herein comprise TRPM4b polypeptides, which are in turn encoded by TRPM4b nucleic acids. The ion channels described herein are preferably formed in HEK-293 cells and comprise one or more novel TRPM4b polypeptides, which exhibit one or more of the unique TRPM4b properties described herein.
    Type: Application
    Filed: May 8, 2002
    Publication date: July 31, 2003
    Inventor: Reinhold Penner
  • Publication number: 20020182635
    Abstract: The present invention relates to the identification and isolation of a novel family of ADP ribose (“ADPR) regulated calcium transmembrane channel polypeptides designated herein as “LTRPC2” (Long Transient Receptor Potential Channel). Channels comprising these polypeptides open in response to concentrations of cytoplasmic ADPR in the micromolar range, exhibit enhanced activity in the presence of high intracellular levels of calcium, and do not respond to depletion or reduction in intracellular calcium stores. The invention further relates to the methods of utilizing LTRPC2 for binding, and the methods for modulating LTRPC2 activity and for measuring LTRPC2 permeability. The invention further relates to the methods of modulating expression of LTRPC2.
    Type: Application
    Filed: November 13, 2001
    Publication date: December 5, 2002
    Inventors: Reinhold Penner, Andrea Fleig